GlaxoSmithKline Pharmaceuticals Ltd
GLAXOGlaxoSmithKline Pharmaceuticals Ltd
GLAXO
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 42.06 | 15.06 | 2.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.65 | 4.77 | 0.76% |
Forecast & Ratings
Detailed Forecastfrom 5 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
GlaxoSmithKline Pharmaceuticals is a pharmaceutical company engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company develops a range of products in pharmaceuticals, vaccines and consumer healthcare.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 3,504.93 | 2,977.08 | 3,029.71 | 2,943.80 | 3,279.21 | 3,850.20 | 3,143.70 | 4,700.86 | 3,365.83 | 3,405.47 | ||||||||||
Raw Materials | 1,514.14 | 1,377.57 | 1,314.38 | 1,299.24 | 1,332.46 | 1,343.30 | 1,294.88 | 1,340.62 | 1,215.92 | 2,480.40 | ||||||||||
| Power & Fuel Cost | 31.17 | 25.97 | 27.82 | 26.44 | 27.94 | 33.36 | 26.08 | 27.83 | 29.60 | |||||||||||
| Employee Cost | 493.02 | 443.37 | 483.01 | 523.40 | 537.20 | 628.55 | 616.16 | 610.23 | 594.99 | |||||||||||
| Selling & Administrative Expenses | 446.77 | 333.63 | 373.99 | 358.84 | 381.41 | 376.88 | 242.05 | 343.67 | 370.30 | |||||||||||
| Operating & Other expenses | 238.32 | 192.78 | 292.00 | 157.73 | 268.39 | 1,073.35 | 357.54 | 215.32 | 248.00 | |||||||||||
EBITDA | 781.51 | 603.76 | 538.51 | 578.15 | 731.81 | 394.76 | 606.99 | 2,163.19 | 907.02 | 925.07 | ||||||||||
| Depreciation/Amortization | 25.35 | 24.95 | 27.08 | 37.99 | 48.59 | 82.68 | 78.60 | 68.19 | 65.77 | 66.31 | ||||||||||
| PBIT | 756.16 | 578.81 | 511.43 | 540.16 | 683.22 | 312.08 | 528.39 | 2,095.00 | 841.25 | 858.76 | ||||||||||
| Interest & Other Items | 0.47 | 0.42 | 0.25 | 0.19 | 0.55 | 6.34 | 3.53 | 2.00 | 1.81 | 1.41 | ||||||||||
| PBT | 755.69 | 578.39 | 511.18 | 539.97 | 682.67 | 305.74 | 524.86 | 2,093.00 | 839.44 | 857.35 | ||||||||||
| Taxes & Other Items | 279.27 | 202.25 | 174.38 | 189.24 | 237.27 | 212.55 | 166.72 | 398.28 | 228.76 | 233.69 | ||||||||||
| Net Income | 476.42 | 376.14 | 336.80 | 350.73 | 445.40 | 93.19 | 358.14 | 1,694.72 | 610.68 | 623.66 | ||||||||||
| EPS | 28.12 | 22.20 | 19.88 | 20.70 | 26.29 | 5.50 | 21.14 | 100.04 | 36.05 | 36.81 | ||||||||||
| DPS | 31.25 | 25.00 | 15.00 | 17.50 | 20.00 | 40.00 | 30.00 | 90.00 | 32.00 | 122.00 | ||||||||||
| Payout ratio | 1.11 | 1.13 | 0.75 | 0.85 | 0.76 | 7.27 | 1.42 | 0.90 | 0.89 | 3.31 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd | 42.95 | 15.06 | 2.07% |
| Sun Pharmaceutical Industries Ltd | 32.81 | 4.69 | 0.99% |
| Cipla Ltd | 34.18 | 4.04 | 0.72% |
| Dr Reddy's Laboratories Ltd | 20.63 | 3.99 | 0.72% |
Price Comparison
Compare GLAXO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Sep 2022
Dec 2022
Mar 2023
Jun 2023
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding GlaxoSmithKline Pharmaceuticals Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Aditya Birla Sun Life ELSS Tax Relief '96 - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.7463% | Percentage of the fund’s portfolio invested in the stock 1.34% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 17/66 (-2) |
ICICI Prudential Large & Mid Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4750% | Percentage of the fund’s portfolio invested in the stock 1.30% | Change in the portfolio weight of the stock over the last 3 months -0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 56/97 (-3) |
ICICI PRUDENTIAL VALUE DISCOVERY FUND - DIRECT PLAN - GROWTH Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4406% | Percentage of the fund’s portfolio invested in the stock 0.35% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 67/92 (-4) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
GLAXO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 2.12%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹21.16 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJun 30, 2023
Dividend/Share
₹32.00
Ex DateEx Date
Jun 30, 2023
Cash Dividend
Ex DateEx DateJul 7, 2022
Dividend/Share
₹60.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateJul 7, 2022
Dividend/Share
₹30.00
Ex DateEx Date
Jul 7, 2022
Cash Dividend
Ex DateEx DateJul 19, 2021
Dividend/Share
₹30.00
Ex DateEx Date
Jul 19, 2021
Cash Dividend
Ex DateEx DateJul 17, 2020
Dividend/Share
₹20.00
Ex DateEx Date
Jul 17, 2020
News & Opinions
Stocks To Watch: Reliance Industries, Jio, LIC, GlaxoSmithKline Pharma, PNB, Sula Vineyards, Nykaa
1 month ago•Bloomberg Quint
GlaxoSmithKline Consolidated June 2023 Net Sales at Rs 761.66 crore, up 2.22% Y-o-Y
2 months ago•Moneycontrol
GlaxoSmithKline Standalone June 2023 Net Sales at Rs 738.02 crore, up 1.17% Y-o-Y
2 months ago•Moneycontrol
GSK Pharma consolidated net profit up 11 per cent
2 months ago•The Hindu Businessline
GlaxoSmithKline Pharma posts 11% rise in Q1 profit on steady vaccine business
2 months ago•Moneycontrol
GSK India net profit grows 13% to Rs 131 crore in Q1FY24
2 months ago•Economic Times
U.S. FDA gives nod for Granules copy of GlaxoSmithKline’s Advil Dual Action tablets
2 months ago•The Hindu
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 2.72%, vs industry avg of 8.45%
Decreasing Market Share
Over the last 5 years, market share decreased from 1.45% to 1.06%
Higher than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.73%, vs industry avg of 9.81%